Key result
Exposure to Thorotrast during cerebral angiography was associated with significantly increased mortality and cancer incidence, primarily driven by liver cancer, leukemia, and benign liver diseases.
Why the study?
Does Thorotrast administration for cerebral angiography increase mortality and cancer incidence in neurological patients?
Cohort (n=2,479)
Does Thorotrast administration for cerebral angiography increase mortality and cancer incidence in neurological patients?
Thorotrast exposure during cerebral angiography is associated with significantly increased mortality and cancer incidence, particularly liver cancer and leukemia.
No takes yet. Share an insight, caveat, or question.
Supports surveillance in historical Thorotrast cohorts; confirms carcinogenicity but leaves open relevance to modern contrasts.
Andersson et al. (1995) conducted a cohort in Neurological patients requiring cerebral angiography (n=2,479). Thorotrast (232ThO2) vs. Cerebral angiography without Thorotrast was evaluated on Mortality and cancer incidence. Exposure to Thorotrast during cerebral angiography was associated with significantly increased mortality and cancer incidence, primarily driven by liver cancer, leukemia, and benign liver diseases.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: